Use: Labeled indications
- Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
- This indication is approved under accelerated approval based on response rate.
- Adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE JAYPIRCA ® is a kinase inhibitor indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. (1.1) This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. (1.2) Adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion. (1.3) 1.1 Mantle Cell Lymphoma JAYPIRCA ® is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
This indication is approved under accelerated approval based on response rate [see Clinical Studies (14.1)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 1.2 Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. 1.3 Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma without 17p deletion JAYPIRCA is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion.
Contraindications
4 CONTRAINDICATIONS None. None (4).
US FDA labelDosing: Adult
- Recommended dosage: 200 mg orally once daily; swallow whole with water, with or without food. Do not cut, crush, or chew tablets. (2.1)
- Manage toxicity using treatment interruption, dosage reduction, or discontinuation. (2.2)
- Reduce dose in patients with severe renal impairment. (2.3, 8.6)
2.1 Recommended Dosage
2.1 Recommended Dosage The recommended dosage of JAYPIRCA is 200 mg orally once daily until disease progression or unacceptable toxicity. Advise patients of the following: Swallow tablets whole with water. Do not cut, crush, or chew tablets. Take JAYPIRCA at the same time each day. JAYPIRCA may be taken with or without food [see Clinical Pharmacology (12.3)].
If a dose of JAYPIRCA is missed by more than 12 hours, do not make up the dose and take the next dose as scheduled.
2.2 Dosage Modifications for Adverse Reactions
2.2 Dosage Modifications for Adverse Reactions Recommended dosage modifications of JAYPIRCA for adverse reactions are presented in Table 1 [see Warnings and Precautions (5.1, 5.2, 5.3, and 5.4)]. Table 1: Recommended Dosage Modification of JAYPIRCA for Adverse Reactions Dose modification is not recommended for asymptomatic lymphocytosis.
Asymptomatic lipase increase may not necessarily warrant dose modification. a Evaluate the benefit-risk before resuming treatment at the same dose for a Grade 4 non-hematological toxicity. Adverse Reaction Occurrences Requiring Dosage Modification Modification (Starting Dosage: 200 mg once daily) Grade 3 or greater non-hematologic toxicity a Absolute neutrophil count < 1 to 0.5 x 10 9 /L with fever and/or infection Absolute neutrophil count < 0.5 x 10 9 /L lasting 7 or more days Platelet count < 50 to 25 x 10 9 /L with bleeding Platelet count < 25 x 10 9 /L First occurrence Interrupt JAYPIRCA until recovery to Grade 1 or baseline; restart at original dosage (200 mg once daily) a.
Second occurrence Interrupt JAYPIRCA until recovery to Grade 1 or baseline; restart at 100 mg once daily. Third occurrence Interrupt JAYPIRCA until recovery to Grade 1 or baseline; restart at 50 mg once daily. Fourth occurrence Discontinue JAYPIRCA.
2.3 Dosage Modifications for Patients with Severe Renal Impairment
2.3 Dosage Modifications for Patients with Severe Renal Impairment For patients with severe renal impairment (eGFR 15-29 mL/min), reduce the JAYPIRCA dose to 100 mg once daily if the current dose is 200 mg once daily otherwise reduce the dose by 50 mg. If the current dosage is 50 mg once daily, discontinue JAYPIRCA [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].
No dosage adjustment of JAYPIRCA is recommended in patients with mild to moderate renal impairment (eGFR 30-89 mL/min).
2.4 Dosage Modifications for Concomitant Use with Strong CYP3A Inhibitors
2.4 Dosage Modifications for Concomitant Use with Strong CYP3A Inhibitors Avoid concomitant use of strong CYP3A inhibitors with JAYPIRCA [see Drug Interactions (7.1), Clinical Pharmacology (12.3)]. If concomitant use of a strong CYP3A inhibitor is unavoidable, reduce the JAYPIRCA dose by 50 mg. If the current dosage is 50 mg once daily, interrupt JAYPIRCA treatment for the duration of strong CYP3A inhibitor use.
After discontinuation of a strong CYP3A inhibitor for 5 half-lives, resume the JAYPIRCA dose that was taken prior to initiating the strong CYP3A inhibitor.
2.5 Dosage Modifications for Concomitant Use with CYP3A Inducers
2.5 Dosage Modifications for Concomitant Use with CYP3A Inducers Avoid concomitant use of strong or moderate CYP3A inducers with JAYPIRCA [see Drug Interactions (7.1), Clinical Pharmacology (12.3)]. If concomitant use with moderate CYP3A inducers is unavoidable and the current dosage of JAYPIRCA is 200 mg once daily, increase the dose to 300 mg.
If the current dosage is 50 mg or 100 mg once daily, increase the dose by 50 mg.
Dosing: Altered kidney function
2.3 Dosage Modifications for Patients with Severe Renal Impairment For patients with severe renal impairment (eGFR 15-29 mL/min), reduce the JAYPIRCA dose to 100 mg once daily if the current dose is 200 mg once daily otherwise reduce the dose by 50 mg. If the current dosage is 50 mg once daily, discontinue JAYPIRCA [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)]. No dosage adjustment of JAYPIRCA is recommended in patients with mild to moderate renal impairment (eGFR 30-89 mL/min).
8.6 Renal Impairment Severe renal impairment (eGFR 15-29 mL/min) increases pirtobrutinib exposure [see Clinical Pharmacology (12.3)]. Reduce the JAYPIRCA dosage in patients with severe renal impairment [see Dosage and Administration (2.3)]. No dosage adjustment of JAYPIRCA is recommended in patients with mild (60-89 mL/min) or moderate (30-59 mL/min) renal impairment.
Patients with Renal Impairment Following a single 200 mg oral dose, the AUC of pirtobrutinib in subjects with severe renal impairment (eGFR 15-29 mL/min) increased by 62% and mean unbound AUC increased by 68% compared to healthy subjects with normal renal function. There were no clinically significant differences in the pharmacokinetics of pirtobrutinib in subjects with mild (eGFR 60-89 mL/min) or moderate renal impairment (eGFR 30-59 mL/min). The effect of renal impairment requiring dialysis on the pharmacokinetics of pirtobrutinib is unknown.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.7 Hepatic Impairment No dosage adjustment of JAYPIRCA is recommended in patients with mild hepatic impairment (total bilirubin ≤ upper limit of normal (ULN) and aspartate aminotransferase (AST) > ULN or total bilirubin > 1 to 1.5 × ULN and any AST), moderate hepatic impairment (total bilirubin > 1.5 to 3 × ULN and any AST), or severe hepatic impairment (total bilirubin > 3 × ULN and any AST) [see Clinical Pharmacology (12.3)].
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness of JAYPIRCA have not been established in pediatric patients.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the patients with MCL who received the 200 mg dose of JAYPIRCA in BRUIN, 93 (78%) were 65 years of age and older and 39 (33%) were 75 years and older [see Clinical Studies (14.1)]. Clinical studies of JAYPIRCA did not include sufficient numbers of patients with MCL who were less than 65 years of age to determine whether older patients respond differently from younger adult patients.
Of the patients with CLL/SLL who received the 200 mg once daily dose of JAYPIRCA in four clinical studies, 480 (61%) were 65 years of age and older and 165 (21%) were 75 years and older [see Clinical Studies (14.2)]. No overall differences in effectiveness were observed between younger and older patients. In the pooled safety population in patients with hematologic malignancies, 720 (62%) were 65 years of age and older, while 266 (23%) were 75 years of age and older.
Patients aged 65 years and older experienced higher rates of Grade 3 and higher adverse reactions and serious adverse reactions compared to patients who were less than 65 years of age.
Dosage forms
Philippines
- Film-coated tablet: 50 mg, 100 mg
Registered products in the Philippines
2 products registered with the Food and Drug Administration (FDA) Philippines list Pirtobrutinib as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
JaypircaPirtobrutinib | 100 mg Film-Coated TabletPCTFE/PVC-Aluminium Blister Pack Foil x7’s (Box of 28’s and 56’s) | Rx | Lilly del Caribe, Inc.United States | Zuellig Pharma Corporation | DR-XY49702 | Apr 29, 2031 | |
JaypircaPirtobrutinib | 50 mg Film-Coated TabletPCTFE/PVC-Aluminium Blister Pack Foil x7’s (Box of 28’s and 56’s) | Rx | Lilly del Caribe, Inc.United States | Zuellig Pharma Corporation | DR-XY49703 | Apr 29, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Tablets: Each 50 mg tablet is blue, arc-triangle shaped, film-coated, and debossed with “Lilly 50” on one side and “6902” on the other side. Each 100 mg tablet is blue, round, film-coated, and debossed with “Lilly 100” on one side and “7026” on the other side. Tablets: 50 mg, 100 mg (3).
Warnings/Precautions
- Infections: Monitor for signs and symptoms of infection, evaluate promptly, and treat. (5.1)
- Hemorrhage: Monitor for bleeding and manage appropriately. (5.2)
- Cytopenias: Monitor complete blood counts during treatment. (5.3)
- Cardiac Arrhythmias: Monitor for symptoms of arrhythmias and manage appropriately. (5.4)
- Second Primary Malignancies: Other malignancies have developed, including skin cancers and other carcinomas. Monitor and advise patients to use sun protection. (5.5)
- Hepatotoxicity, Including Drug-Induced Liver Injury: Monitor hepatic function throughout treatment. (5.6)
- Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of potential risk to a fetus and to use effective contraception. (5.7, 8.1, 8.3)
5.1 Infections
5.1 Infections Fatal and serious infections (including bacterial, viral, or fungal infections) and opportunistic infections have occurred in patients treated with JAYPIRCA. Across all clinical trials, Grade 3 or higher infections occurred in 23% of 1153 patients, most commonly pneumonia (13%), with fatal infections occurring in 4.3% of patients.
Sepsis occurred in 4.8% of patients and febrile neutropenia in 3.3%. In patients with CLL/SLL, Grade 3 or higher infections occurred in 24% of patients, with fatal infections occurring in 5%. Opportunistic infections after treatment with JAYPIRCA have included, but are not limited to, Pneumocystis jirovecii pneumonia and fungal infection [see Adverse Reactions (6.1)].
Consider prophylaxis, including vaccinations and antimicrobial prophylaxis, in patients who are at increased risk for infections, including opportunistic infections. Monitor patients for signs and symptoms of infection, evaluate promptly, and treat appropriately. Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA [see Dosage and Administration (2.2)].
5.2 Hemorrhage
5.2 Hemorrhage Fatal and serious hemorrhage has occurred with JAYPIRCA. Major hemorrhage (defined as Grade 3 or higher bleeding or any central nervous system bleeding) occurred in 3.1% of 1153 patients treated with JAYPIRCA across all clinical trials, including gastrointestinal hemorrhage; fatal hemorrhage occurred in 0.3% of patients.
Bleeding of any grade, excluding bruising and petechiae, occurred in 18% of patients [see Adverse Reactions (6.1)]. Major hemorrhage occurred in 1.8% of patients taking JAYPIRCA without antithrombotic agents and 1.3% of patients taking JAYPIRCA with antithrombotic agents. Consider the risks and benefits of antithrombotic agents when co-administered with JAYPIRCA.
Monitor patients for signs of bleeding. Based on severity of bleeding, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA [see Dosage and Administration (2.2)]. Consider the benefit-risk of withholding JAYPIRCA for 3 to 7 days pre- and post-surgery depending upon the type of surgery and risk of bleeding.
5.3 Cytopenias
5.3 Cytopenias JAYPIRCA can cause cytopenias, including neutropenia, thrombocytopenia, and anemia. Across all clinical trials, Grade 3 or 4 cytopenias, including decreased neutrophils (26%), decreased platelets (9%), and decreased hemoglobin (9%) developed in patients treated with JAYPIRCA. Grade 4 decreased neutrophils developed in 14% of patients and Grade 4 decreased platelets developed in 4.3% of patients [see Adverse Reactions (6.1)].
Monitor complete blood counts regularly during treatment. Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA [see Dosage and Administration (2.2)].
5.4 Cardiac Arrhythmias
5.4 Cardiac Arrhythmias Cardiac arrhythmias, including atrial fibrillation and atrial flutter, were reported in recipients of JAYPIRCA. Atrial fibrillation or flutter were reported in 3.1% of patients, with Grade 3 or 4 atrial fibrillation or flutter reported in 1.6% of 1153 patients across all clinical trials [see Adverse Reactions (6.1)].
Other serious cardiac arrhythmias such as supraventricular tachycardia and cardiac arrest occurred in 0.3% of patients. Patients with cardiac risk factors, such as hypertension, or previous arrhythmias may be at increased risk. Monitor for signs and symptoms of arrhythmias (e.g., palpitations, dizziness, syncope, dyspnea) and manage appropriately.
Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA [see Dosage and Administration (2.2)].
5.5 Second Primary Malignancies
5.5 Second Primary Malignancies Second primary malignancies, including non-skin carcinomas, developed in 10% of 1153 patients treated with JAYPIRCA monotherapy across all clinical trials. The most frequent malignancy was non-melanoma skin cancer, reported in 4.9% of 1153 patients. Other second primary malignancies included solid tumors (including genitourinary and breast cancers) and melanoma.
Advise patients to use sun protection and monitor patients for the development of second primary malignancies.
5.6 Hepatotoxicity, Including Drug-Induced Liver Injury
5.6 Hepatotoxicity, Including Drug-Induced Liver Injury Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of drug-induced liver injury (DILI), has occurred in patients treated with Bruton tyrosine kinase inhibitors, including JAYPIRCA. Evaluate bilirubin and transaminases at baseline and throughout treatment with JAYPIRCA.
For patients who develop abnormal liver tests after JAYPIRCA, monitor more frequently for liver test abnormalities and clinical signs and symptoms of hepatic toxicity. If DILI is suspected, withhold JAYPIRCA. Upon confirmation of DILI, discontinue JAYPIRCA.
5.7 Embryo-Fetal Toxicity
5.7 Embryo-Fetal Toxicity Based on findings in animals, JAYPIRCA can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of pirtobrutinib to pregnant rats during the period of organogenesis caused embryo-fetal toxicity including embryo-fetal mortality and malformations at maternal exposures (AUC) approximately 3-times the recommended dose of 200 mg once daily.
Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with JAYPIRCA and for one week after the last dose [see Use in Specific Populations (8.1, 8.3)].
Drug interactions
- Strong CYP3A Inhibitors: Avoid concomitant use. If concomitant use is unavoidable, reduce the JAYPIRCA dose. (2.4, 7.1)
- Strong or Moderate CYP3A Inducers: Avoid concomitant use. If concomitant use of moderate CYP3A inducers is unavoidable, increase the JAYPIRCA dose. (2.5, 7.1)
- Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates: For substrates where minimal concentration changes may increase the risk of adverse reactions, follow recommendations for co-administration with CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP inhibitors provided in their approved product labeling. (7.2)
7.1 Effect of Other Drugs
7.1 Effect of Other Drugs on JAYPIRCA Strong CYP3A Inhibitors Pirtobrutinib is a CYP3A substrate. Concomitant use of JAYPIRCA with a strong CYP3A inhibitor increased pirtobrutinib systemic exposure [see Clinical Pharmacology (12.3)], which may increase the risk of JAYPIRCA adverse reactions. Avoid concomitant use of strong CYP3A inhibitors during treatment with JAYPIRCA.
If concomitant use of strong CYP3A inhibitors is unavoidable, reduce the JAYPIRCA dosage [see Dosage and Administration (2.4)]. Strong or Moderate CYP3A Inducers Concomitant use of JAYPIRCA with a strong or moderate CYP3A inducer decreased pirtobrutinib systemic exposure [see Clinical Pharmacology (12.3)], which may reduce JAYPIRCA efficacy.
Avoid concomitant use of JAYPIRCA with strong or moderate CYP3A inducers. If concomitant use of moderate CYP3A inducers is unavoidable, increase the JAYPIRCA dosage [see Dosage and Administration (2.5)].
7.2 Effect
7.2 Effect of JAYPIRCA on Other Drugs Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates JAYPIRCA is a P-gp inhibitor, a moderate CYP2C8 and BCRP inhibitor, and a weak CYP2C19 and CYP3A inhibitor. Concomitant use of JAYPIRCA with sensitive P-gp, CYP2C8, BCRP, CYP2C19, or CYP3A substrates increased their plasma concentrations [see Clinical Pharmacology (12.3)], which may increase the risk of adverse reactions related to these substrates for drugs which are sensitive to minimal concentration changes.
Follow recommendations for sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP substrates provided in their approved product labeling.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Metabolism Pirtobrutinib is primarily metabolized by CYP3A4 and direct glucuronidation by UGT1A8 and UGT1A9, in vitro.
Drug Interaction Studies Clinical Studies and Model-Informed Approaches Strong CYP3A Inhibitors: Co-administration of a single 200 mg dose of pirtobrutinib with itraconazole (strong CYP3A inhibitor) increased AUC of pirtobrutinib by 49%.
Moderate CYP3A Inhibitors: Verapamil and diltiazem (moderate CYP3A inhibitors) are predicted to increase the AUC of pirtobrutinib by 30% and 20%, respectively.
Strong CYP3A inducers: Coadministration of a single 200 mg dose of pirtobrutinib with rifampin (strong CYP3A inducer) decreased the AUC of pirtobrutinib by 71%.
Moderate CYP3A Inducers: Efavirenz and bosentan (moderate CYP3A inducers) are predicted to decrease the AUC of pirtobrutinib by 49% and 27%, respectively.
P-glycoprotein (P-gp) inhibitors: No clinically significant differences in pirtobrutinib pharmacokinetics were observed when co-administered with itraconazole (P-gp inhibitor).
CYP3A Substrates: Pirtobrutinib increased the AUC and C max of orally administered midazolam (sensitive CYP3A substrate) by 70% and 58%, respectively.
CYP2C8 Substrates: Pirtobrutinib increased the AUC and C max of repaglinide (sensitive CYP2C8 substrate) by 130% and 98%, respectively.
Adverse reactions
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Infections [see Warnings and Precautions (5.1)] Hemorrhage [see Warnings and Precautions (5.2)] Cytopenias [see Warnings and Precautions (5.3)] Atrial Fibrillation and Atrial Flutter [see Warnings and Precautions (5.4)] Second Primary Malignancies [see Warnings and Precautions (5.5)] Hepatotoxicity, including DILI [see Warnings and Precautions (5.6)] Most common adverse reactions (≥ 30%), including laboratory abnormalities, are neutrophil count decreased and hemoglobin decreased. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be compared to rates in the clinical trials of another drug and may not reflect the rates observed in the general patient population.
The data in the WARNINGS AND PRECAUTIONS reflect exposure to JAYPIRCA as a single-agent, administered at 200 mg once daily in 1153 patients with hematologic malignancies in the four clinical studies. Among these 1153 patients, the median duration of exposure was 18 months; 76% were exposed for at least 6 months and 66% were exposed for at least one year.
In this pooled safety population, the most common (≥ 30%) adverse reactions, including laboratory abnormalities, were decreased neutrophil count (56%) and decreased hemoglobin (38%). Mantle Cell Lymphoma BRUIN The safety of JAYPIRCA was evaluated in the BRUIN trial, an open-label, multicohort, single-arm study in patients with previously treated MCL who received a prior BTK inhibitor [see Clinical Studies (14.1)].
The trial required a platelet count ≥ 50 x 10 9 /L, absolute neutrophil count ≥ 0.75 x 10 9 /L, hepatic transaminases ≤ 2.5 times upper limit of normal (ULN), and an ECOG performance status of 0 to 2. The trial excluded patients with active central nervous system (CNS) involvement by lymphoma, significant cardiovascular disease, major bleeding or grade ≥ 3 arrhythmia with a prior BTK inhibitor, prolonged QTc interval, or need for a strong CYP3A inhibitor or inducer or strong P-gp inhibitor.
Patients received JAYPIRCA 200 mg orally once daily until disease progression or unacceptable toxicity (n = 128); 36% were exposed for 6 months or longer and 10% were exposed for at least one year. The median number of prior therapies was 3 (range: 1-9). The median age was 71 years (range: 46 to 88 years) and 80% of patients were male.
Race was reported for all patients; 78% were White, 14% were Asian, 2.3% were Black, and 2.3% were Hispanic or Latino. Serious adverse reactions occurred in 38% of patients who received JAYPIRCA. Serious adverse reactions that occurred in ≥ 2% of patients were pneumonia (14%), COVID-19 (4.7%), musculoskeletal pain (3.9%), hemorrhage (2.3%), pleural effusion (2.3%), and sepsis (2.3%).
Fatal adverse reactions within 28 days of the last dose of JAYPIRCA occurred in 7% of patients, most commonly due to infections (4.7%) including COVID-19 (3.1% of all patients). Adverse reactions led to dose reductions in 4.7%, treatment interruption in 32%, and permanent discontinuation of JAYPIRCA in 9%. Adverse reactions that resulted in dosage modification in > 5% of patients included pneumonia and neutropenia.
Adverse reactions which resulted in permanent discontinuation of JAYPIRCA in > 1% of patients included pneumonia. The most common adverse reactions (≥ 15%), excluding laboratory terms, were fatigue, musculoskeletal pain, diarrhea, edema, dyspnea, pneumonia, and bruising. Table 2 summarizes select adverse reactions in BRUIN.
Table 2: Adverse Reactions (≥ 10%) in Patients with MCL Who Received JAYPIRCA in BRUIN JAYPIRCA 200 mg once daily N = 128 a Each term listed includes other related terms. b includes 1 fatality from COVID-19 pneumonia. c includes 1 fatality from hemorrhage. Adverse Reactions a All Grades (%) Grade 3 or 4 (%) General Disorders Fatigue 29 1.6 Edema 18 0.8 Fever 13 - Musculoskeletal and Connective Tissue Disorders Musculoskeletal pain 27 3.9 Arthritis or arthralgia 12 0.8 Gastrointestinal Disorders Diarrhea 19 - Constipation 13 - Abdominal pain 11 0.8 Nausea 11 - Respiratory, thoracic, and mediastinal disorders Dyspnea 17 2.3 Cough 14 - Injury Bruising 16 - Infections Pneumonia 16 b 14 Upper respiratory tract infections 10 0.8 Nervous system disorders Peripheral neuropathy 14 0.8 Dizziness 10 - Skin and subcutaneous disorders Rash 14 - Vascular disorders Hemorrhage 11 c 3.1 Clinically relevant adverse reactions in < 10% include vision changes, memory changes, headache, urinary tract infection, herpesvirus infection, and tumor lysis syndrome.
Table 3 summarizes laboratory abnormalities in BRUIN. Table 3: Select Laboratory Abnormalities (≥ 10%) That Worsened from Baseline in Patients with MCL Who Received JAYPIRCA in BRUIN a The denominator used to calculate the rate varied from 90 to 127 based on the number of patients with a baseline value and at least one post-treatment value.
Laboratory Abnormality JAYPIRCA a 200 mg once daily All Grades (%) Grade 3 or 4 (%) Hematology Hemoglobin decreased 42 9 Platelet count decreased 39 14 Neutrophil count decreased 36 16 Lymphocyte count decreased 32 15 Chemistry Creatinine increased 30 1.6 Calcium decreased 19 1.6 AST increased 17 1.6 Potassium decreased 13 1.6 Sodium decreased 13 - Lipase increased 12 4.4 Alkaline phosphatase increased 11 - ALT increased 11 1.6 Potassium increased 11 0.8 Grade 4 laboratory abnormalities in > 5% of patients included neutrophils decreased (10%), platelets decreased (7%), and lymphocytes decreased (6%). Lymphocytosis: Upon initiation of JAYPIRCA, a temporary increase in lymphocyte counts (defined as absolute lymphocyte count increased ≥ 50% from baseline and a post-baseline value ≥ 5,000/μL) occurred in 34% of MCL patients in BRUIN.
The median time to onset of lymphocytosis was 1.1 weeks, with 75% of cases occurring within 2.1 weeks, and the median duration was 11 weeks. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma BRUIN The safety of JAYPIRCA was evaluated in the BRUIN trial, an open-label, multicohort, single-arm study in 110 patients with relapsed or refractory CLL/SLL, with 98% having received at least two prior lines of systemic therapy including a covalent BTK inhibitor and a BCL-2 inhibitor [see Clinical Studies (14.2)].
The trial required a platelet count ≥ 50 x 10 9 /L, absolute neutrophil count ≥ 0.75 x 10 9 /L, hepatic transaminases ≤ 2.5 times upper limit of normal (ULN), and an ECOG performance status of 0 to 2. The trial excluded patients with active central nervous system (CNS) involvement by lymphoma, significant cardiovascular disease, major bleeding, uncontrolled or symptomatic arrhythmias, prolonged QTc interval, or need for a strong CYP3A inhibitor or inducer or strong P-gp inhibitor.
Patients received JAYPIRCA 200 mg orally once daily until disease progression or unacceptable toxicity (N = 110); 60% were exposed for at least 1 year and 14% were exposed for at least two years. The median age was 68 years (range: 41 to 88 years) and 67% of patients were male. Race was reported in 110 (100%) patients; of these patients, 89% were White, 4.5% were Black, 1.8% were Asian, and 1.8% were Hispanic or Latino.
The median number of prior therapies was 5 (range: 1-11). Serious adverse reactions occurred in 56% of patients who received JAYPIRCA. Serious adverse reactions that occurred in ≥ 5% of patients were pneumonia (18%), COVID-19 (9%), sepsis (7%), and febrile neutropenia (7%). Fatal adverse reactions within 28 days of the last dose of JAYPIRCA occurred in 11% of patients, most commonly due to infections (10%), including sepsis (5%) and COVID-19 (2.7%).
Adverse reactions led to dose reductions in 3.6%, treatment interruption in 42%, and permanent discontinuation of JAYPIRCA in 9%. Adverse reactions which resulted in dose reductions of JAYPIRCA in > 1% of patients included neutropenia. Adverse reactions which resulted in treatment interruptions of JAYPIRCA in > 5% of patients included pneumonia, neutropenia, febrile neutropenia, and COVID-19.
Adverse reactions which resulted in permanent discontinuation of JAYPIRCA in > 1% of patients included second primary malignancy, COVID-19, and sepsis. The most common adverse reactions (≥ 20%), excluding laboratory terms, were fatigue, bruising, cough, musculoskeletal pain, COVID-19, diarrhea, pneumonia, abdominal pain, dyspnea, hemorrhage, edema, nausea, pyrexia, and headache.
Table 4 summarizes select adverse reactions for patients treated on BRUIN. Table 4: Adverse Reactions (≥ 10%) in Patients with CLL/SLL Who Received JAYPIRCA in BRUIN JAYPIRCA 200 mg once daily N = 110 Adverse Reactions a All Grades (%) Grade 3 or 4 (%) a Each term listed includes other related terms. b Includes COVID-19 pneumonia.
Includes 1 fatality from COVID-19 and 2 fatalities from COVID-19 pneumonia. c Includes COVID-19 pneumonia. Includes 2 fatalities from COVID-19 pneumonia and 1 fatality from pneumonia. d Includes preferred terms hemorrhage, intracranial hemorrhage, and gastrointestinal hemorrhage. e Includes preferred terms memory impairment, confusional state, encephalopathy, mental status changes. f Includes preferred terms second primary malignancy and nonmelanoma skin cancers. 1 fatality from metastatic malignant melanoma. g Includes preferred terms renal failure, chronic kidney disease, acute kidney injury. h Includes preferred terms supraventricular tachycardia, sinus tachycardia, atrial fibrillation.
General Disorders Fatigue 36 2.7 Edema 21 0 Pyrexia 20 2.7 Injury Bruising 36 0 Fall 14 0.9 Respiratory, thoracic, and mediastinal disorders Cough 33 0 Dyspnea 22 2.7 Mucositis 12 0.9 Musculoskeletal and Connective Tissue Disorders Musculoskeletal pain 32 0.9 Arthritis or arthralgia 19 1.8 Infections COVID-19 28 b 7 Pneumonia 27 c 16 Upper respiratory tract infections 13 2.7 Respiratory tract infection 11 1.8 Gastrointestinal Disorders Diarrhea 26 0 Abdominal pain 25 2.7 Nausea 21 0 Constipation 14 0 Vascular disorders Hemorrhage 22 d 2.7 Hypertension 12 5 Nervous system disorders Headache 20 0.9 Peripheral neuropathy 16 3.6 Dizziness 15 0 Neurological changes 12 e 2.7 Skin and subcutaneous disorders Rash 19 0.9 Psychiatric disorders Insomnia 14 0 Neoplasms benign, malignant and unspecified Second primary malignancy 13 f 2.7 Renal and urinary disorders Renal insufficiency 12 g 6 Metabolism and nutrition disorders Decreased appetite 12 0 Cardiac disorders Supraventricular tachycardia 10 h 5 Clinically relevant adverse reactions in < 10% include vision changes, lower respiratory tract infection, urinary tract infection, herpesvirus infection, and tumor lysis syndrome. Table 5 summarizes laboratory abnormalities in BRUIN.
Table 5: Select Laboratory Abnormalities (≥ 20%) That Worsened from Baseline in Patients with CLL/SLL Who Received JAYPIRCA in BRUIN Laboratory Abnormality JAYPIRCA a 200 mg once daily All Grades (%) Grade 3 or 4 (%) a The denominator used to calculate the rate varied from 83 to 108 based on the number of patients with a baseline value and at least one post-treatment value. Hematology Neutrophil count decreased 63 45 Hemoglobin decreased 48 19 Platelet count decreased 30 15 Lymphocyte count decreased 23 8 Chemistry Calcium decreased 40 2.8 Sodium decreased 30 0 ALT increased 23 2.8 AST increased 23 1.9 Creatinine increased 23 0 Lipase increased 21 7 Alkaline phosphatase increased 21 0 Grade 4 laboratory abnormalities in > 5% of patients included neutrophils decreased (23%). **Lymphocytosis: Upon initiation of JAYPIRCA, a temporary increase in lymphocyte counts (defined as absolute lymphocyte count increased ≥ 50% from baseline and a post-baseline value ≥ 5,000/μL) occurred in 64% of CLL/SLL patients in BRUIN.
The median time to onset of lymphocytosis was 1.1 weeks, with 75% of cases occurring within 1.1 weeks, and the median duration was 19 weeks. BRUIN CLL-321 The safety of JAYPIRCA was evaluated in BRUIN CLL-321, a randomized, multicenter, open-label active control trial [see Clinical Studies (14.2)]. The trial enrolled patients with relapsed or refractory CLL/SLL who were previously treated with a covalent BTK inhibitor.
The trial required a platelet count ≥ 50 x 10 9 /L, absolute neutrophil count ≥ 0.75 x 10 9 /L, and an estimated creatinine clearance ≥ 30 mL/min. The trial excluded patients with significant cardiovascular disease including uncontrolled or symptomatic arrhythmias, or major bleeding on a prior covalent BTK inhibitor. The trial enrolled 238 patients who were randomized in a 1:1 fashion to receive JAYPIRCA given orally once daily at a dose of 200 mg until disease progression or unacceptable toxicity or investigator's choice of either idelalisib in combination with a rituximab product or bendamustine in combination with a rituximab product [see Clinical Studies (14.2)].
One hundred sixteen patients received JAYPIRCA and 109 patients received investigator's choice of idelalisib and rituximab or bendamustine and rituximab. The median duration of treatment with JAYPIRCA was 15 months with 78% on treatment for greater than 6 months and 66% for greater than 12 months. Serious adverse reactions occurred in 47% of patients who received JAYPIRCA.
Serious adverse reactions that occurred in ≥ 3% of patients were pneumonia (21%), COVID-19 (5%), and sepsis (3.4%). Fatal adverse reactions within 30 days of the last dose of JAYPIRCA occurred in 8% of patients, most commonly due to infections (7%), COVID-19 (5%) and pneumonia (3.4%). Adverse reactions led to permanent discontinuation of JAYPIRCA in 17% of patients, dose reductions in 10%, and treatment interruption in 51%.
Adverse reactions which resulted in dose reductions of JAYPIRCA in > 1% of patients included neutropenia. Adverse reactions which resulted in treatment interruptions of JAYPIRCA in > 5% of patients included pneumonia, neutropenia, hemorrhage and COVID-19. Adverse reactions which resulted in permanent discontinuation of JAYPIRCA in > 1% of patients included pneumonia, COVID-19, neutropenia, anemia, and cardiac arrhythmias.
The most common adverse reactions (≥ 20%), excluding laboratory terms, were pneumonia and upper respiratory tract infections. Table 6 summarizes select adverse reactions for patients treated on BRUIN CLL-321. Table 6: Adverse Reactions (≥ 10%) in Patients with CLL/SLL Who Received JAYPIRCA in BRUIN CLL-321 a Each term listed includes other related terms. b Includes COVID-19 pneumonia.
Includes 3 fatalities from COVID-19 pneumonia, 3 fatalities from pneumonia, for JAYPIRCA; includes 3 fatalities from pneumonia for IR and 1 fatality from COVID-19 pneumonia for BR. c Includes COVID-19 pneumonia. Includes 3 fatalities from COVID-19 pneumonia and 3 fatalities from COVID-19 for JAYPIRCA and 1 fatality from COVID-19 for IR and 1 fatality from COVID-19 pneumonia for BR.
JAYPIRCA Investigator's Choice N = 116 N = 109 Adverse Reactions a All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Pneumonia 28 b 16 16 b 11 Upper respiratory tract infections 21 0.9 10 0 COVID-19 17 c 0.9 19 c 4.6 General Disorders Fatigue 19 2.6 26 1.8 Edema 12 0 8 0 Cough 19 0 19 0 Fever 13 0.9 27 0.9 Nausea 11 0.9 20 0 Headache 11 0.9 16 0 Hemorrhage 16 2.6 7 0 Musculoskeletal and Connective Tissue Disorders Musculoskeletal pain 19 0.9 13 0 Gastrointestinal Disorders Diarrhea 16 0 31 6 Skin and Subcutaneous Disorders Rash 14 2.6 20 4.6 Clinically relevant adverse reactions in <10% in patients who received JAYPIRCA include vision changes, urinary tract infection, herpes virus infection, and hypertension. Table 7 summarizes laboratory abnormalities in BRUIN CLL-321.
Table 7: Select Laboratory Abnormalities (≥ 20%) That Worsened from Baseline in Patients with CLL/SLL Who Received JAYPIRCA in BRUIN CLL-321 a The denominator used to calculate the rate varied from 113 to 114 in the JAYPIRCA arm and from 29 to 31 for bendamustine plus rituximab, and 75 for idelalisib plus rituximab, based on the number of patients with a baseline value and at least one posttreatment value. Laboratory Abnormality JAYPIRCA a Investigator's Choice a All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Hematology Neutrophil count decreased 54 26 67 27 Hemoglobin decreased 45 10 42 8 Platelet count decreased 37 17 42 9 Chemistry ALT increased 25 1.8 46 14 Creatinine increased 25 0 20 1 Calcium decreased 23 0.9 31 0 Sodium decreased 22 0.9 21 1 Bilirubin increased 21 0.9 21 1 BRUIN CLL-313 The safety of JAYPIRCA was evaluated in the BRUIN CLL-313 trial, a randomized, multicenter, open-label, active control trial [see Clinical Studies (14.2)].
The trial enrolled patients with treatment naïve CLL/SLL without deletion of chromosome 17p13.1 (del 17p). The trial required a platelet count ≥ 75 × 10 9 /L, absolute neutrophil count ≥ 0.75 × 10 9 /L, and creatinine clearance ≥ 40 mL/min). The trial excluded patients with 17p deletion, significant cardiovascular disease including uncontrolled or symptomatic arrhythmias, active uncontrolled autoimmune cytopenias, or an active second malignancy.
The trial enrolled 282 patients who were randomized 1:1 to receive JAYPIRCA given orally once daily at a dose of 200 mg until disease progression or unacceptable toxicity or bendamustine in combination with a rituximab product (BR) for 6 cycles. One hundred forty patients received JAYPIRCA, and 132 patients received BR.
The median duration of treatment with JAYPIRCA was 32 months with 92% of patients on treatment for greater than 24 months. Serious adverse reactions occurred in 28% of patients who received JAYPIRCA. Serious adverse reactions that occurred in ≥ 3% of patients included pneumonia (5%). Fatal adverse reactions within 30 days of the last dose of JAYPIRCA occurred in 1 (0.7%) patient, due to septic shock.
Adverse reactions led to permanent discontinuation of JAYPIRCA in 4.3% of patients, dose reductions in 3.6%, and treatment interruption in 35%. Adverse reactions which resulted in dose reductions of JAYPIRCA in > 1% of patients included pruritus. Adverse reactions which resulted in treatment interruptions of JAYPIRCA in > 5% of patients included COVID-19.
The most common adverse reactions (≥ 20%), excluding laboratory terms, were upper respiratory tract infections, rash, and COVID-19. Table 8 summarizes select adverse reactions for patients treated on BRUIN CLL-313. Table 8: Adverse Reactions (≥ 10%) in Patients with Previously Untreated CLL/SLL Without 17p Deletion Who Received JAYPIRCA in BRUIN CLL-313 a Each term listed includes other related terms. b Includes COVID-19 pneumonia. c Includes bronchitis, respiratory tract infection, influenza, influenza like illness, respiratory tract infection bacterial.
JAYPIRCA Bendamustine + Rituximab Product N = 140 N = 132 Adverse Reactions a All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Infections Upper respiratory tract infections 27 2.1 8 0 COVID-19 21 b 0.7 10 b 2.3 Respiratory tract infection 11 c 1.4 6 c 0 Urinary tract infection 10 1.4 1.5 0.8 Skin and Subcutaneous Disorders Rash 22 0.7 26 2.3 General Disorders Hemorrhage 12 0.7 1.5 0 Musculoskeletal and Connective Tissue Disorders Musculoskeletal pain 17 0.7 8 0.8 Arthralgia 12 0.7 1.5 0 Injury Bruising 11 0 0 0 Vascular Disorder Hypertension 10 4.3 4.5 3.0 Clinically relevant adverse reactions in <10% of patients who received JAYPIRCA include pneumonia and headache. Table 9 summarizes laboratory abnormalities in BRUIN CLL-313.
Table 9: Select Laboratory Abnormalities (≥ 20%) That Worsened from Baseline in Patients with Previously Untreated CLL/SLL Without 17p Deletion Who Received JAYPIRCA in BRUIN CLL-313 a The denominator used to calculate the rate was 140 in the JAYPIRCA arm and varied from 128 to 129 for the BR arm, based on the number of patients with a baseline value and at least one post-treatment value. Laboratory Abnormality JAYPIRCA a Bendamustine + Rituximab Product a All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Hematology Neutrophil count decreased 48 14 78 45 Hemoglobin decreased 24 6 34 9 Chemistry Bilirubin increased 30 5 9 2.3 ALT increased 27 2.9 23 0 Sodium increased 20 0 13 0
Adverse reaction frequency tables (US label) US FDA label
| JAYPIRCA 200 mg once daily | ||
|---|---|---|
| N = 128 | ||
| a Each term listed includes other related terms. | ||
| b includes 1 fatality from COVID-19 pneumonia. | ||
| c includes 1 fatality from hemorrhage. | ||
| Adverse Reactions a | All Grades (%) | Grade 3 or 4 (%) |
| General Disorders | ||
| Fatigue | 29 | 1.6 |
| Edema | 18 | 0.8 |
| Fever | 13 | - |
| Musculoskeletal and Connective Tissue Disorders | ||
| Musculoskeletal pain | 27 | 3.9 |
| Arthritis or arthralgia | 12 | 0.8 |
| Gastrointestinal Disorders | ||
| Diarrhea | 19 | - |
| Constipation | 13 | - |
| Abdominal pain | 11 | 0.8 |
| Nausea | 11 | - |
| Respiratory, thoracic, and mediastinal disorders | ||
| Dyspnea | 17 | 2.3 |
| Cough | 14 | - |
| Injury | ||
| Bruising | 16 | - |
| Infections | ||
| Pneumonia | 16 b | 14 |
| Upper respiratory tract infections | 10 | 0.8 |
| Nervous system disorders | ||
| Peripheral neuropathy | 14 | 0.8 |
| Dizziness | 10 | - |
| Skin and subcutaneous disorders | ||
| Rash | 14 | - |
| Vascular disorders | ||
| Hemorrhage | 11 c | 3.1 |
| a The denominator used to calculate the rate varied from 90 to 127 based on the number of patients with a baseline value and at least one post-treatment value. | ||
| Laboratory Abnormality | JAYPIRCAa 200 mg once daily | |
| All Grades (%) | Grade 3 or 4 (%) | |
| Hematology | ||
| Hemoglobin decreased | 42 | 9 |
| Platelet count decreased | 39 | 14 |
| Neutrophil count decreased | 36 | 16 |
| Lymphocyte count decreased | 32 | 15 |
| Chemistry | ||
| Creatinine increased | 30 | 1.6 |
| Calcium decreased | 19 | 1.6 |
| AST increased | 17 | 1.6 |
| Potassium decreased | 13 | 1.6 |
| Sodium decreased | 13 | - |
| Lipase increased | 12 | 4.4 |
| Alkaline phosphatase increased | 11 | - |
| ALT increased | 11 | 1.6 |
| Potassium increased | 11 | 0.8 |
| JAYPIRCA 200 mg once daily | ||
|---|---|---|
| N = 110 | ||
| Adverse Reactions a | All Grades (%) | Grade 3 or 4 (%) |
| a Each term listed includes other related terms. | ||
| b Includes COVID-19 pneumonia. Includes 1 fatality from COVID-19 and 2 fatalities from COVID-19 pneumonia. | ||
| c Includes COVID-19 pneumonia. Includes 2 fatalities from COVID-19 pneumonia and 1 fatality from pneumonia. | ||
| d Includes preferred terms hemorrhage, intracranial hemorrhage, and gastrointestinal hemorrhage. | ||
| e Includes preferred terms memory impairment, confusional state, encephalopathy, mental status changes. | ||
| f Includes preferred terms second primary malignancy and nonmelanoma skin cancers. 1 fatality from metastatic malignant melanoma. | ||
| g Includes preferred terms renal failure, chronic kidney disease, acute kidney injury. | ||
| h Includes preferred terms supraventricular tachycardia, sinus tachycardia, atrial fibrillation. | ||
| General Disorders | ||
| Fatigue | 36 | 2.7 |
| Edema | 21 | 0 |
| Pyrexia | 20 | 2.7 |
| Injury | ||
| Bruising | 36 | 0 |
| Fall | 14 | 0.9 |
| Respiratory, thoracic, and mediastinal disorders | ||
| Cough | 33 | 0 |
| Dyspnea | 22 | 2.7 |
| Mucositis | 12 | 0.9 |
| Musculoskeletal and Connective Tissue Disorders | ||
| Musculoskeletal pain | 32 | 0.9 |
| Arthritis or arthralgia | 19 | 1.8 |
| Infections | ||
| COVID-19 | 28b | 7 |
| Pneumonia | 27c | 16 |
| Upper respiratory tract infections | 13 | 2.7 |
| Respiratory tract infection | 11 | 1.8 |
| Gastrointestinal Disorders | ||
| Diarrhea | 26 | 0 |
| Abdominal pain | 25 | 2.7 |
| Nausea | 21 | 0 |
| Constipation | 14 | 0 |
| Vascular disorders | ||
| Hemorrhage | 22d | 2.7 |
| Hypertension | 12 | 5 |
| Nervous system disorders | ||
| Headache | 20 | 0.9 |
| Peripheral neuropathy | 16 | 3.6 |
| Dizziness | 15 | 0 |
| Neurological changes | 12e | 2.7 |
| Skin and subcutaneous disorders | ||
| Rash | 19 | 0.9 |
| Psychiatric disorders | ||
| Insomnia | 14 | 0 |
| Neoplasms benign, malignant and unspecified | ||
| Second primary malignancy | 13f | 2.7 |
| Renal and urinary disorders | ||
| Renal insufficiency | 12g | 6 |
| Metabolism and nutrition disorders | ||
| Decreased appetite | 12 | 0 |
| Cardiac disorders | ||
| Supraventricular tachycardia | 10h | 5 |
| Laboratory Abnormality | JAYPIRCAa 200 mg once daily | |
|---|---|---|
| All Grades (%) | Grade 3 or 4 (%) | |
| a The denominator used to calculate the rate varied from 83 to 108 based on the number of patients with a baseline value and at least one post-treatment value. | ||
| Hematology | ||
| Neutrophil count decreased | 63 | 45 |
| Hemoglobin decreased | 48 | 19 |
| Platelet count decreased | 30 | 15 |
| Lymphocyte count decreased | 23 | 8 |
| Chemistry | ||
| Calcium decreased | 40 | 2.8 |
| Sodium decreased | 30 | 0 |
| ALT increased | 23 | 2.8 |
| AST increased | 23 | 1.9 |
| Creatinine increased | 23 | 0 |
| Lipase increased | 21 | 7 |
| Alkaline phosphatase increased | 21 | 0 |
| a Each term listed includes other related terms. | ||||
| b Includes COVID-19 pneumonia. Includes 3 fatalities from COVID-19 pneumonia, 3 fatalities from pneumonia, for JAYPIRCA; includes 3 fatalities from pneumonia for IR and 1 fatality from COVID-19 pneumonia for BR. | ||||
| c Includes COVID-19 pneumonia. Includes 3 fatalities from COVID-19 pneumonia and 3 fatalities from COVID-19 for JAYPIRCA and 1 fatality from COVID-19 for IR and 1 fatality from COVID-19 pneumonia for BR. | ||||
| JAYPIRCA | Investigator's Choice | |||
| N = 116 | N = 109 | |||
| Adverse Reactions a | All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) |
| Pneumonia | 28b | 16 | 16b | 11 |
| Upper respiratory tract infections | 21 | 0.9 | 10 | 0 |
| COVID-19 | 17c | 0.9 | 19c | 4.6 |
| General Disorders | ||||
| Fatigue | 19 | 2.6 | 26 | 1.8 |
| Edema | 12 | 0 | 8 | 0 |
| Cough | 19 | 0 | 19 | 0 |
| Fever | 13 | 0.9 | 27 | 0.9 |
| Nausea | 11 | 0.9 | 20 | 0 |
| Headache | 11 | 0.9 | 16 | 0 |
| Hemorrhage | 16 | 2.6 | 7 | 0 |
| Musculoskeletal and Connective Tissue Disorders | ||||
| Musculoskeletal pain | 19 | 0.9 | 13 | 0 |
| Gastrointestinal Disorders | ||||
| Diarrhea | 16 | 0 | 31 | 6 |
| Skin and Subcutaneous Disorders | ||||
| Rash | 14 | 2.6 | 20 | 4.6 |
| a The denominator used to calculate the rate varied from 113 to 114 in the JAYPIRCA arm and from 29 to 31 for bendamustine plus rituximab, and 75 for idelalisib plus rituximab, based on the number of patients with a baseline value and at least one posttreatment value. | ||||
| Laboratory Abnormality | JAYPIRCA a | Investigator's Choice a | ||
| All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) | |
| Hematology | ||||
| Neutrophil count decreased | 54 | 26 | 67 | 27 |
| Hemoglobin decreased | 45 | 10 | 42 | 8 |
| Platelet count decreased | 37 | 17 | 42 | 9 |
| Chemistry | ||||
| ALT increased | 25 | 1.8 | 46 | 14 |
| Creatinine increased | 25 | 0 | 20 | 1 |
| Calcium decreased | 23 | 0.9 | 31 | 0 |
| Sodium decreased | 22 | 0.9 | 21 | 1 |
| Bilirubin increased | 21 | 0.9 | 21 | 1 |
| a Each term listed includes other related terms. | ||||
| b Includes COVID-19 pneumonia. | ||||
| c Includes bronchitis, respiratory tract infection, influenza, influenza like illness, respiratory tract infection bacterial. | ||||
| JAYPIRCA | Bendamustine + Rituximab Product | |||
| N = 140 | N = 132 | |||
| Adverse Reactions a | All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) |
| Infections | ||||
| Upper respiratory tract infections | 27 | 2.1 | 8 | 0 |
| COVID-19 | 21b | 0.7 | 10b | 2.3 |
| Respiratory tract infection | 11c | 1.4 | 6c | 0 |
| Urinary tract infection | 10 | 1.4 | 1.5 | 0.8 |
| Skin and Subcutaneous Disorders | ||||
| Rash | 22 | 0.7 | 26 | 2.3 |
| General Disorders | ||||
| Hemorrhage | 12 | 0.7 | 1.5 | 0 |
| Musculoskeletal and Connective Tissue Disorders | ||||
| Musculoskeletal pain | 17 | 0.7 | 8 | 0.8 |
| Arthralgia | 12 | 0.7 | 1.5 | 0 |
| Injury | ||||
| Bruising | 11 | 0 | 0 | 0 |
| Vascular Disorder | ||||
| Hypertension | 10 | 4.3 | 4.5 | 3.0 |
| a The denominator used to calculate the rate was 140 in the JAYPIRCA arm and varied from 128 to 129 for the BR arm, based on the number of patients with a baseline value and at least one post-treatment value. | ||||
| Laboratory Abnormality | JAYPIRCA a | Bendamustine + Rituximab Product a | ||
| All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) | |
| Hematology | ||||
| Neutrophil count decreased | 48 | 14 | 78 | 45 |
| Hemoglobin decreased | 24 | 6 | 34 | 9 |
| Chemistry | ||||
| Bilirubin increased | 30 | 5 | 9 | 2.3 |
| ALT increased | 27 | 2.9 | 23 | 0 |
| Sodium increased | 20 | 0 | 13 | 0 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Based on findings from animal studies, JAYPIRCA can cause fetal harm when administered to a pregnant woman. There are no available data on JAYPIRCA use in pregnant women to evaluate for a drug-associated risk. In an animal reproduction study, administration of pirtobrutinib to pregnant rats during organogenesis resulted in adverse developmental outcomes, including structural abnormalities, altered fetal growth, and embryo-fetal mortality, at maternal exposures approximately 3-times those in patients at the recommended daily dose of 200 mg (see Data).
Advise pregnant women of the potential risk to a fetus. The background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies. Data Animal Data In an embryo-fetal development study in rats, pregnant animals were administered oral doses of pirtobrutinib at up to 500 mg/kg twice daily during the period of organogenesis.
Doses ≥ 375 mg/kg twice daily caused decreased fetal body weights and increased incidence of malformations and variations in the urinary tract (including absent or abnormal ureters and kidneys), reproductive tract (malpositioned ovaries and misshapen uterus), and bone (misshapen sternebrae). At 500 mg/kg twice daily, total resorption was observed.
At 375 mg/kg twice daily in rats, the maternal systemic exposures (AUC) were approximately 3 times the human exposure at 200 mg once daily.
Mechanism of action
12.1 Mechanism of action Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK. BTK is a signaling protein of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Pirtobrutinib binds to wild type BTK and BTK harboring C481 mutations, leading to inhibition of BTK kinase activity.
In nonclinical studies, pirtobrutinib inhibited BTK-mediated B-cell CD69 expression and inhibited malignant B-cell proliferation. Pirtobrutinib showed dose-dependent anti-tumor activities in BTK wild type and BTK C481S mutant mouse xenograft models.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics At the recommended dosage of 200 mg once daily, pirtobrutinib trough concentrations exceeded the BTK IC 96. BTK occupancy is maintained throughout the dosing interval, regardless of the intrinsic rate of BTK turnover. Cardiac Electrophysiology The effect of a single 900 mg dose of pirtobrutinib (equivalent to approximately 2 times higher than the concentrations achieved at steady state at the recommended dosage of 200 mg once daily) on the QTc interval was evaluated in a placebo-controlled and positive-controlled study in 30 healthy subjects.
Pirtobrutinib had no clinically meaningful effect on the change in QTcF interval (i.e., > 10 ms) and there was no relationship between pirtobrutinib exposure and change in QTc interval.
Pharmacokinetics
Elimination The effective half-life of pirtobrutinib is approximately 19.9 hours and the mean (CV%) apparent clearance is 1.98 L/h (32.1 %).
Excretion Following a single radiolabeled dose of pirtobrutinib 200 mg to healthy subjects, 37% of the dose was recovered in feces (18% unchanged) and 57% in urine (10% unchanged).
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics The pharmacokinetics of pirtobrutinib were characterized in healthy subjects and in patients with cancer. Pirtobrutinib exposure (AUC) and C max increases proportionally following single oral doses ranging from 300 mg to 800 mg (1.5 to 4 times the approved recommended dosage) and once daily doses ranging from 25 – 300 mg (0.125 to 1.5 times the recommended dosage).
Steady state was achieved within 5 days of once daily dosing, and the mean (CV%) accumulation ratio was 1.63 (26.7%) based on AUC after administration of 200 mg dosages. Following administration of the recommended dosage, the geometric mean (CV%) steady-state AUC and C max of pirtobrutinib were 97100 h*ng/mL (35.5%) and 6690 ng/mL (24%), respectively.
The geometric mean (CV%) AUC 0-24 and C max of pirtobrutinib on Cycle 1 Day 8 were 81800 h*ng/mL (66.6%) and 3670 ng/mL (89.5%), respectively. Absorption The absolute bioavailability of pirtobrutinib after a single oral 200 mg dose is 85.5% (range 75.9% to 90.9%). The median time (range) to reach peak plasma concentration (tmax) is approximately 2 hours (0.833 to 4.15 hours).
Effect of Food No clinically significant differences in the pharmacokinetics of pirtobrutinib were observed following administration of a high-fat, high-calorie meal (approximately 800 to 1000 calories with 150 calories from protein, 250 calories from carbohydrate, and 500 to 600 calories from fat) to healthy subjects. A high-fat meal decreased the C max of pirtobrutinib by 23% and delayed t max by 1 hour.
There was no effect on pirtobrutinib AUC. Distribution The mean apparent central volume of distribution of pirtobrutinib is 35.4 L. Human protein binding of pirtobrutinib is 96% and is independent of concentration in vitro. Mean blood-to-plasma ratio is 0.79. Elimination The effective half-life of pirtobrutinib is approximately 19.9 hours and the mean (CV%) apparent clearance is 1.98 L/h (32.1 %).
Metabolism Pirtobrutinib is primarily metabolized by CYP3A4 and direct glucuronidation by UGT1A8 and UGT1A9, in vitro. Excretion Following a single radiolabeled dose of pirtobrutinib 200 mg to healthy subjects, 37% of the dose was recovered in feces (18% unchanged) and 57% in urine (10% unchanged). Specific Populations There were no clinically significant differences in the pharmacokinetics of pirtobrutinib based on age (range 22 to 95 years), sex, race/ethnicity (White 81%, Asian 11%), body weight (range 35.7 to 154 kg), mild (total bilirubin ≤ upper limit of normal (ULN) and aspartate aminotransferase (AST) > ULN or total bilirubin > 1 to 1.5 × ULN and any AST), moderate (total bilirubin > 1.5 to 3 × ULN and any AST), or severe (total bilirubin > 3 × ULN and any AST) hepatic impairment.
The effect of other races/ethnicities on the pharmacokinetics of pirtobrutinib is unknown. Patients with Renal Impairment Following a single 200 mg oral dose, the AUC of pirtobrutinib in subjects with severe renal impairment (eGFR 15-29 mL/min) increased by 62% and mean unbound AUC increased by 68% compared to healthy subjects with normal renal function.
There were no clinically significant differences in the pharmacokinetics of pirtobrutinib in subjects with mild (eGFR 60-89 mL/min) or moderate renal impairment (eGFR 30-59 mL/min). The effect of renal impairment requiring dialysis on the pharmacokinetics of pirtobrutinib is unknown. Drug Interaction Studies Clinical Studies and Model-Informed Approaches Strong CYP3A Inhibitors: Co-administration of a single 200 mg dose of pirtobrutinib with itraconazole (strong CYP3A inhibitor) increased AUC of pirtobrutinib by 49%.
Moderate CYP3A Inhibitors: Verapamil and diltiazem (moderate CYP3A inhibitors) are predicted to increase the AUC of pirtobrutinib by 30% and 20%, respectively. Strong CYP3A inducers: Coadministration of a single 200 mg dose of pirtobrutinib with rifampin (strong CYP3A inducer) decreased the AUC of pirtobrutinib by 71%. Moderate CYP3A Inducers: Efavirenz and bosentan (moderate CYP3A inducers) are predicted to decrease the AUC of pirtobrutinib by 49% and 27%, respectively.
Gastric Reducing Agents: No clinically significant differences in pirtobrutinib pharmacokinetics were observed when co-administered with omeprazole (a proton pump inhibitor). P-glycoprotein (P-gp) inhibitors: No clinically significant differences in pirtobrutinib pharmacokinetics were observed when co-administered with itraconazole (P-gp inhibitor).
CYP3A Substrates: Pirtobrutinib increased the AUC and C max of orally administered midazolam (sensitive CYP3A substrate) by 70% and 58%, respectively. Pirtobrutinib did not have a clinically meaningful effect on the exposure of intravenously administered midazolam. CYP2C8 Substrates: Pirtobrutinib increased the AUC and C max of repaglinide (sensitive CYP2C8 substrate) by 130% and 98%, respectively.
CYP2C19 Substrates: Pirtobrutinib increased the AUC and C max of omeprazole (sensitive CYP2C19 substrate) by 56% and 49%, respectively. P-gp Substrates: A single 200 mg dose of pirtobrutinib increased the AUC and C max of digoxin (sensitive P-gp substrate) by 17% and 51%, respectively. Multiple doses of pirtobrutinib (200 mg daily) further increased the AUC and C max of digoxin (sensitive P-gp substrate) up to 35% and 55%, respectively.
BCRP Substrates: Multiple doses of pirtobrutinib (200 mg daily) increased the AUC and C max of rosuvastatin (sensitive BCRP substrate) by 140% and 146%, respectively. CYP1A2 and CYP2C9 Substrates: Pirtobrutinib did not have a clinically meaningful effect on the exposures of caffeine (sensitive CYP1A2 substrate) or S-warfarin (moderate sensitive CYP2C9 substrate).
In Vitro Studies Cytochrome P450 (CYP) Enzymes: Pirtobrutinib inhibits CYP2C8, CYP2C9, CYP3A, CYP1A2, CYP2B6, CYP2C19, and CYP2D6. Pirtobrutinib induces CYP3A4, CYP3A5, CYP2B6, and CYP2C19. Transporter Systems: Pirtobrutinib inhibits P-gp and BCRP, but not OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, or MATE2-K. Pirtobrutinib is not a substrate of the hepatic transporters.
Pirtobrutinib is a substrate of P-gp and BCRP, but not OCT1, OATP1B1, OATP1B3, or BSEP.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. JAYPIRCA · Eli Lilly and Company [US FDA-approved label, version 16, October 2, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd551845-0878-49a4-860f-839b83f6b801
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .